Our mission is to make a novel therapeutic approach a reality in Peritoneal Dialysis (PD) – an area where clinicians and patients saw disappointingly little innovation in decades. Zytoprotec, a biomedical company founded in 2007, has consistently moved its lead product – PDprotec® – from basic research through preclinical and clinical development. The product is currently prepared to enter a pivotal Phase III clinical trial.
R&D:Research conducted by Zytoprotec has shown that the protective mechanism of cells can be restored by intervention with cytoprotective compounds. This offers the potential to prevent cells, tissues and whole organs from damage, thereby improving the quality of live and the survival of patients. With PDprotec®, Zytoprotec is applying this new approach to the area of renal replacement therapy.